HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

This study is evaluating whether combining a liver-targeted chemotherapy infusion (called HAIC — hepatic arterial infusion chemotherapy) with immunotherapy (PD-1 inhibitors) and a targeted drug (lenvatinib) can help people with advanced liver cancer (hepatocellular carcinoma, HCC) whose cancer stopped responding to standard systemic treatments. **You may be eligible if...** - You have confirmed liver cancer (HCC) - Your cancer is at an advanced stage with tumor invasion into the main liver blood vessel (portal vein) - You have already received and failed standard systemic treatment recommended for your stage - You have received at least 2 cycles of HAIC - Your liver function is acceptable (Child-Pugh A or B) **You may NOT be eligible if...** - More than 3 months have passed between failure of systemic therapy and starting this combination treatment - You have another active malignancy - The required timing of treatments cannot be met Talk to your doctor to see if this trial is right for you.